Kolon Life Science Inc Asset Resilience Ratio

Latest as of March 2025: 1.22%

Kolon Life Science Inc asset resilience ratio. Kolon Life Science Inc (102940) has an Asset Resilience Ratio of 1.22% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Kolon Life Science Inc fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩7.33 Billion
≈ $4.97 Million USD Cash + Short-term Investments

Total Assets

₩601.96 Billion
≈ $407.94 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Kolon Life Science Inc (2016–2024)

Asset resilience ratio of Kolon Life Science Inc from 2016 to 2024. This chart shows how Kolon Life Science Inc's Asset Resilience Ratio has changed over time. Read 102940 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Kolon Life Science Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 102940 current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩7.33 Billion 1.22%
Short-term Investments ₩0.00 0%
Total Liquid Assets ₩7.33 Billion 1.22%

Asset Resilience Insights

  • Limited Liquidity: Kolon Life Science Inc maintains only 1.22% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kolon Life Science Inc Industry Peers by Asset Resilience Ratio

Compare Kolon Life Science Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
Pharmaceuticals 6.87%
ST Pharm Co.Ltd
KQ:237690
Pharmaceuticals 7.72%
NatureCell Co.Ltd
KQ:007390
Pharmaceuticals 0.00%
Oscotec Inc
KQ:039200
Pharmaceuticals 66.73%
Komipharm International Co. Ltd
KQ:041960
Pharmaceuticals 0.00%
Mezzion Pharma Co.Ltd
KQ:140410
Pharmaceuticals 0.00%
Aprogen Healthcare & Games Inc
KQ:109960
Pharmaceuticals 6.55%
Caregen Co.Ltd
KQ:214370
Pharmaceuticals 4.58%

Kolon Life Science Inc Asset Resilience Ratio by Year (2016–2024)

Kolon Life Science Inc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Kolon Life Science Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.96% ₩12.42 Billion
≈ $8.41 Million
₩419.56 Billion
≈ $284.33 Million
+0.54pp
2023-12-31 2.42% ₩7.48 Billion
≈ $5.07 Million
₩309.44 Billion
≈ $209.70 Million
+0.39pp
2022-12-31 2.03% ₩6.37 Billion
≈ $4.32 Million
₩314.12 Billion
≈ $212.87 Million
-9.87pp
2021-12-31 11.89% ₩27.91 Billion
≈ $18.91 Million
₩234.66 Billion
≈ $159.02 Million
+5.84pp
2020-12-31 6.05% ₩15.03 Billion
≈ $10.19 Million
₩248.34 Billion
≈ $168.29 Million
-1.46pp
2019-12-31 7.51% ₩20.91 Billion
≈ $14.17 Million
₩278.29 Billion
≈ $188.60 Million
+1.41pp
2018-12-31 6.10% ₩37.77 Billion
≈ $25.60 Million
₩618.90 Billion
≈ $419.42 Million
-4.89pp
2017-12-31 11.00% ₩78.83 Billion
≈ $53.42 Million
₩716.80 Billion
≈ $485.76 Million
-27.88pp
2016-12-31 38.88% ₩137.85 Billion
≈ $93.42 Million
₩354.57 Billion
≈ $240.29 Million
--
pp = percentage points

About Kolon Life Science Inc

KQ:102940 Korea Pharmaceuticals
Market Cap
$99.35 Million
₩146.60 Billion KRW
Market Cap Rank
#19044 Global
#918 in Korea
Share Price
₩12850.00
Change (1 day)
+3.55%
52-Week Range
₩12380.00 - ₩70800.00
All Time High
₩163572.85
About

Kolon Life Science Inc. provides biopharmaceuticals, active pharmaceutical ingredients, pyrithione antimicrobials, and water solutions primarily in South Korea. Its biopharmaceutical product under development comprise KLS-1020, a cancer vaccine; KLS-3021, a oncolytic viral therapy; and KLS-2031 for treatment for neuropathic pain. The company also provides active pharmaceutical ingredients for ant… Read more